Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins

Journal of Virology

Volumn 87, Issue 12, 2013, Pages 6560-6568

  Lin, Wen Hsuan W ^a,d,e   Vilalta, Adrian ^b   Adams, Robert J ^c   Rolland, Alain ^b   Sullivan, Sean M ^b   Griffin, Diane E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b VICAL INC   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e Pathway Genomics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; MEASLES VACCINE; MEASLES VIRUS HEMAGGLUTININ FUSION PROTEIN DNA VACCINE; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; VAXFECTIN; VIRUS RNA;

ADJUVANT THERAPY; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BONE MARROW CELL; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; LOW DRUG DOSE; MEASLES; MEASLES VACCINATION; NEEDLELESS BIOJECTOR; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; RNA ANALYSIS; SYRINGE; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; HEMAGGLUTININS, VIRAL; INTERFERON-GAMMA; INTERLEUKIN-17; MACACA MULATTA; MEASLES; MEASLES VACCINE; PHOSPHATIDYLETHANOLAMINES; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VIRAL FUSION PROTEINS;

ANIMALIA; MACACA; MACACA MULATTA; MEASLES VIRUS;

EID: 84878602116     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00635-13     Document Type: Article

References (83)

1. Nandy R, Handzel T, Zaneidou M, Biey J, Coddy RZ, Perry R, Strebel P, Cairns L. 2006. Case-fatality rate during a measles outbreak in eastern Niger in 2003. Clin. Infect. Dis. 42:322-328.
2. Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM. 2009. Estimates of measles case fatality ratios: a comprehensive review of community- based studies. Int. J. Epidemiol. 38:192-205.
3. Moss WJ, Griffin DE. 2006. Global measles elimination. Nat. Rev. Microbiol. 4:900-908.
4. Center for Disease Control. 2007. Progress in global measles control and mortality reduction, 2000-2006. MMWR Morb. Mortal. Wkly. Rep. 56: 1237-1242.
5. Moss WJ, Griffin DE. 2012. Measles. Lancet 379:153-164.
6. Simons E, Ferrari M, Fricks J, Wannemuehler K, Anand A, Burton A, Strebel P. 2012. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 379:2173-2178.
7. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. 1977. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:715-718.
8. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. 1998. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280:527-532.
9. Scott S, Moss WJ, Cousens S, Beeler JA, Audet SA, Mugala N, Quinn TC, Griffin DE, Cutts FT. 7 A.D. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin. Infect. Dis. 45:1417-1424.
10. Moss WJ, Monze M, Ryon JJ, Quinn TC, Griffin DE, Cutts F. 2002. Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin. Infect. Dis. 35:189-196.
11. Embree JE, Datta P, Stackiw W, Sekla L, Braddick M, Kreiss JK, Pamba H, Wamola I, Ndinya-Achola JO, Law BJ. 1992. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J. Infect. Dis. 165:262-267.
12. Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgonne H, Kimman TG. 2006. Preclinical and clinical safety studies on DNA vaccines. Hum. Vaccin. 2:45-53.
13. Donnelly JJ, Wahren B, Liu MA. 2005. DNA vaccines: progress and challenges. J. Immunol. 175:633-639.
14. Denis-Mize KS, Dupuis M, Singh M, Woo C, Ugozzoli M, O'Hagan DT, Donnelly JJ, Ott G, III, McDonald DM. 2003. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic micro particles. Cell. Immunol. 225:12-20.
15. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, Kumar S, Wu TC. 2003. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112:109-117.
16. Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. 2003. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 9:33-39.
17. Kutzler MA, Weiner DB. 2004. Developing DNA vaccines that call to dendritic cells. J. Clin. Invest. 114:1241-1244.
18. Kutzler MA, Weiner DB. 2008. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9:776-788.
19. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE. 1993. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. U. S. A. 90:11307-11311.
20. Parker SE, Vahlsing HL, Serfilippi LM, Franklin CL, Doh SG, Gromkowski SH, Lew D, Manthorpe M, Norman J. 1995. Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum. Gene Ther. 6:575-590.
21. Sullivan SM, Doukas J, Hartikka J, Smith L, Rolland A. 2010. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert. Opin. Drug Deliv. 7:1433-1446.
22. Hartikka J, Bozoukova V, Ferrari M, Sukhu L, Enas J, Sawdey M, Wloch MK, Tonsky K, Norman J, Manthorpe M, Wheeler CJ. 2001. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19:1911-1923.
23. Nukuzuma C, Ajiro N, Wheeler CJ, Konishi E. 2003. Enhancing effect of vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice. Viral Immunol. 16:183-189.
24. Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P. 2004. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. U. S. A. 101: 13601-13606.
25. Sedegah M, Rogers WO, Belmonte A, Belmonte M, Banania G, Patterson N, Ferrari M, Kaslow DC, Carucci DJ, Richie TL, Doolan DL. 2006. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 24:1921-1927.
26. Hahn UK, Aichler M, Boehm R, Beyer W. 2006. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine 24:4595-4597.
27. Margalith M, Vilalta A. 2006. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet. Vaccines Ther. 4:2.
28. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ, Rolland A, Kaslow DC, Smith LR. 2007. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum. Vaccine 3:157-164.
29. Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM. 2012. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J. Gen. Virol. 93:1305-1315.
30. Hartikka J, Bozoukova V, Morrow J, Rusalov D, Shiapobersky M, Wei Q, Boutsaboualoy S, Ye M, Wloch MK, Doukas J, Sullivan S, Rolland A, Smith LR. 2012. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum. Vaccin. Immunother. 8:1595-1600.
31. Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. 2012. A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 30:7046-7051.
32. Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, Polack FP, Rolland A, Vilalta A, Griffin DE. 2008. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin. Vaccine Immunol. 15:1214-1221.
33. Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M, Teneza- Mora N, Raviprakash K. 2012. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine 30:336-341.
34. Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA. 2004. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine 22:2261-2272.
35. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, Al-Ibrahim MS, Kabongo ML, Steigbigel R, Belshe RB, Kitt ER, Chu AH, Moss RB. 2010. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28:2565-2572.
36. Dorig RE, Marcil A, Chopra A, Richardson CD. 1993. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75:295-305.
37. Naniche D, Varior-Krishnan G, Cervoni F, Wild F, Rossi B, Rabourdin- Combe C, Gerlier D. 1993. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67:6025-6032.
38. Tatsuo H, Ono N, Tanaka K, Yanagi Y. 2000. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406:893-898.
39. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VHJ, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray PBJ, Cichutek K, von Messling V, Lopez M, Cattaneo R. 2011. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480:530-533.
40. Noyce RS, Bondre DG, Lin Sisson L-TG, Tsao MS, Richardson CD, Ha MN. 2011. Tumor cell marker PVRL4 (Nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 7:1002240.
41. Santiago C, Bjorling E, Stehle T, Casasnovas JM. 2002. Distinct kinetics for binding of the CD46 and SLAM receptors to overlapping sites in the measles virus hemagglutinin protein. J. Biol. Chem. 277:32294-32301.
42. Masse N, Barrett T, Muller CP, Wild TF, Buckland R. 2002. Identification of a second major site for CD46 binding in the hemagglutinin protein from a laboratory strain of measles virus (MV): potential consequences for wild-type MV infection. J. Virol. 76:13034-13038.
43. Manchester M, Eto DS, Valsamakis A, Liton PB, Fernandez-Munoz R, Rota PA, Bellini WJ, Forthal DN, Oldstone MB. 2000. Clinical isolates of measles virus use CD46 as a cellular receptor. J. Virol. 74:3967-3974.
44. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. 2004. Selectively receptor-blind measles viruses: identification of residues necessary for SLAM or CD46-induced fusion and their localization on a new hemagglutinin structural model. J. Virol. 78:302-313.
45. Schneider U, von Messling V, Devaux P, Cattaneo R. 2002. Efficiency of measles virus entry and dissemination through different receptors. J. Virol. 76:7460-7467.
46. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider- Schaulies J. 2002. Analysis of receptor (CD46, CD150) usage by measles virus. J. Gen. Virol. 83:1431-1436.
47. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa HY. 2001. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J. Virol. 75:4399-4401.
48. Yanagi Y, Ono N, Tatsuo H, Hashimoto K, Minagawa H. 2002. Measles virus receptor SLAM (CD150). Virology 299:155-161.
49. Ota MO, Ndhlovu Z, Oh S, Piyasirisilp S, Berzofsky JA, Moss WJ, Griffin DE. 2007. Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8 T cell response during measles and after vaccination. J. Infect. Dis. 195:1799-1807.
50. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE. 2003. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 9:1209-1213.
51. Polack FP, Auwaerter PG, Lee S-H, Nousari HC, Valsamakis A, Leiferman KM, Diwan A, Adams RJ, Griffin DE. 1999. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusioninhibiting antibody. Nat. Med. 5:629-634.
52. Polack F, Lee S, Permar S, Manyara E, Nousari H, Jeng Y, Mustafa F, Valsamakis A, Adams R, Robinson H, Griffin D. 2000. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat. Med. 6:776-781.
53. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. 1990. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162:1036-1042.
54. Van Binnendijk RS, Poelen MCM, van Amerongen G, de Vries P, Osterhaus ADME. 1997. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:524-532.
55. Pan CH, Valsamakis A, Colella T, Nair N, Adams RJ, Polack FP, Greer CE, Perri S, Polo JM, Griffin DE. 2005. Inaugural article: modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc. Natl. Acad. Sci. U. S. A. 102:11581-11588.
56. Zhu Y, Rota P, Wyatt L, Tamin A, Rozenblatt S, Lerche N, Moss B, Bellini W, McChesney M. 2000. Evaluation of recombinant vaccinia virus-measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 276:202-213.
57. Griffin DE, Lin WH, Pan CH. 2012. Measles virus, immune control and persistence. FEMS Microbiol. Rev. 36:649-662.
58. Benner R, Hijmans W, Haaijman JJ. 1981. The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin. Exp. Immunol. 46:1-8.
59. Pasetti MF, Resendiz-Albor A, Ramirez K, Stout R, Papania M, Adams RJ, Polack FP, Ward BJ, Burt D, Chabot S, Ulmer J, Barry EM, Levine MM. 2007. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. Clin. Pharmacol. Ther. 82:672-685.
60. Ramshaw IA, Ramsay AJ. 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21:163-165.
61. Elgueta R, de Vries VC, Noelle RJ. 2010. The immortality of humoral immunity. Immunol. Rev. 236:139-150.
62. Tourigny MR, Ursini-Siegel J, Lee H, Toellner KM, Cunningham AF, Franklin DS, Ely S, Chen M, Qin XF, Xiong Y, MacLennan IC, Chen- Kiang S. 2002. CDK inhibitor p18INK4c is required for the generation of functional plasma cells. Immunity 17:179-189.
63. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. 2010. Plasma cell development and survival. Immunol. Rev. 237:140-159.
64. Amanna IJ, Slifka MK. 2010. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol. Rev. 236:125-138.
65. McChesney MB, Miller CJ, Rota PA, Zhu Y, Antipa L, Lerche NW, Ahmed R, Bellini WJ. 1997. Experimental measles. 1. Pathogenesis in the normal and the immunized host. Virology 233:74-84.
66. Pan C-H, Greer CE, Hauer D, Legg HS, Lee E-Y, Bergen MJ, Lau B, Adams RJ, Polo JM, Griffin DE. 2010. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J. Virol. 84:3798-3807.
67. Blaschitz C, Raffatellu M. 2010. Th17 cytokines and the gut mucosal barrier. J. Clin. Immunol. 30:196-203.
68. Gaffen SL. 2011. Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol. 23:613-619.
69. Kim JS, Jordan MS. 2012. Diversity of IL-17-producing T lymphocytes. Cell. Mol. Life Sci. doi:10.1007/s00018-012-1163-6.
70. Chien YH, Zeng X, Prinz I. 2012. The natural and the inducible: interleukin (IL)-17-producing γδ T cells. Trends Immunol. 34:151-154.
71. Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, Ivanov II, Littman DR, O'Shea JJ. 2009. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206:35-41.
72. Ramirez-Carrozzi V, Sambandam A, Luis E, Lin Z, Jeet S, Lesch J, Hackney J, Kim J, Zhou M, Lai J, Modrusan Z, Sai T, Lee W, Xu M, Caplazi P, Diehl L, de VJ, Balazs M, Gonzalez L, Jr, Singh H, Ouyang W, Pappu R. 2011. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat. Immunol. 12:1159-1166.
73. Pappu R, Rutz S, Ouyang W. 2012. Regulation of epithelial immunity by IL-17 family cytokines. Trends Immunol. 33:343-349.
74. Reynolds JM, Martinez GJ, Nallaparaju KC, Chang SH, Wang YH, Dong C. 2012. Cutting edge: regulation of intestinal inflammation and barrier function by IL-17C. J. Immunol. 189:4226-4230.
75. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, Godinez I, Sankaran S, Paixao TA, Gordon MA, Kolls JK, Dandekar S, Baumler AJ. 2008. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat. Med. 14:421-428.
76. Onishi RM, Gaffen SL. 2010. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129:311-321.
77. Chen J, Tong J, Liu H, Liu Y, Su Z, Wang S, Shi Y, Zheng D, Sandoghchian S, Geng J, Xu H. 2012. Increased frequency of Th17 cells in the peripheral blood of children infected with enterovirus 71. J. Med. Virol. 84:763-767.
78. Lin WH, Kouyos RD, Adams RJ, Grenfell BT, Griffin DE. 2012. Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc. Natl. Acad. Sci. U. S. A. 109:14989-14994.
79. Hartigan-O'Connor DJ, Hirao LA, McCune JM, Dandekar S. 2011. Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr. Opin. HIV AIDS 6:221-227.
80. Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, Zaffiri L, Tryniszewska E, Tsai WP, Vaccari M, Parks RW, Venzon D, Douek DC, O'Shea JJ, Franchini G. 2008. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal. Immunol. 1:279-288.
81. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, Mold J, Swainson L, Barbour JD, Baskin CR, Palermo R, Pandrea I, Miller CJ, Katze MG, McCune JM. 2009. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 5:e1000295. doi:10.1371/journal.ppat.1000295.
82. Nigam P, Kwa S, Velu V, Amara RR. 2011. Loss of IL-17-producing CD8 T cells during late chronic stage of pathogenic simian immunodeficiency virus infection. J. Immunol. 186:745-753.
83. Ryzhakov G, Lai CC, Blazek K, To KW, Hussell T, Udalova I. 2011. IL-17 boosts proinflammatory outcome of antiviral response in human cells. J. Immunol. 187:5357-5362.